Challenges and Solutions for Pharmaceutical Oligonucleotide Analysis Provided by Agilent

An advanced light scattering detector enables accurate measurement of molecular weight and molecular size of molecules in solution for biochemical analysis.

Achieve excellent reproducibility and high-precision analysis! '1260 Infinity II Bio-SEC Multi-Detector System' Size exclusion chromatography (SEC) is a standard analytical method for measuring and quantifying monomers, dimers, aggregates, and potential degradation products, and is one of the common methods required for regulatory approval. With advanced light scattering detectors, accurate measurement of molecular weight and molecular size of molecules in solution is made possible, while simultaneously achieving higher sensitivity in the detection of aggregates in the analysis of biomacromolecules. 【Features】 ■ Measure molecular weight and molecular size with accuracy and high reproducibility ■ High-sensitivity detection of aggregates with a low dead volume light scattering detector ■ Accurate measurement of molecular size and molecular weight through advanced detection ■ Reduced need for data verification and re-analysis due to excellent reproducibility ■ Metal-free flow path achieves low surface activity and high salt concentration resistance *For more details, please refer to the PDF document or feel free to contact us.*

• Separation device
• Analytical Equipment and Devices

Introduction of each pharmaceutical item! In addition to the specified columns, test items and others are also included.

On our website, we introduce HPLC columns that comply with the 18th edition of the Japanese Pharmacopoeia (Notification No. 220 by the Ministry of Health, Labour and Welfare, dated June 7, 2021). We have listed pharmaceuticals such as "Actinomycin D," "Aclarubicin," "Acrinol Hydrate," and "Azathioprine" by each item. Additionally, if there are no catalog products for the corresponding structure of fillers or column sizes, we indicate "No applicable products." There is a possibility that we can propose custom columns, so please contact us if you have any requests. [Items Listed (Partial)] ■ Actinomycin D ■ Aclarubicin ■ Acrinol Hydrate ■ Azathioprine ■ Acyclovir *For more details, please refer to the related links or feel free to contact us.

• others

[Speaker] Naomasa Shibuya, Department Manager Data Marketing Unit, Strategy and Platform Division East Japan Railway Company Marketing Headquarters [Key Lecture Content] East Japan Railway Company announced a new group management vision, "Yusho 2034," aimed at realizing a rich life for all people by July 2025. In addition to the railway transportation business, we will further expand lifestyle service businesses (non-railway) such as station facilities, station buildings, hotels, and real estate, promoting human-centered marketing focused on our customers. To achieve this, data marketing utilizing usage history from Suica and JRE Point members is essential. It is not enough to simply implement tools or acquire analytical techniques; it is crucial to cultivate personnel who understand the business and can conduct appropriate data analysis and strategy planning. We will also introduce the development of job-type personnel in data marketing, which we began recruiting in 2024. In this lecture, I will discuss the key points for advancing data marketing within a business company, incorporating case studies.

[Lecturers] Mitsubishi UFJ Research and Consulting Co., Ltd. Consulting Business Division Sustainability Business Unit, Sustainability Strategy Department, Group 1 Senior Manager Ryo Maeda Consultant Keiro Shimada [Key Lecture Content] Towards achieving carbon neutrality by 2050, Japan is advancing the introduction of a carbon pricing system. This lecture will explain the overview of carbon pricing and the price determination mechanisms for fossil fuel levies and specific business burdens, and will discuss future price forecasts and their impact on companies. Furthermore, it will organize the latest trends in GX-ETS Phase 2 and carbon credits, as well as issues related to credit supply and demand and utilization, and will propose measures that companies need to take in light of the introduction of the carbon pricing system. [Lecture Items] 1. Trends in the carbon pricing system 2. Trends in carbon credits 3. Required responses from companies 4. Q&A / Business card exchange

We will be exhibiting at the "International Frontier Industry Messe," one of the largest comprehensive exhibitions in western Japan. September 4 (Thursday) - 5 (Friday), 2025 Kobe International Exhibition Hall 2nd floor, Hall 1, Booth Number P-74 Inside the Aioi Chamber of Commerce booth We sincerely look forward to your visit.

In recent years, the pharmaceutical and medical industries have faced urgent challenges, including the digitization of standard operating procedures (SOPs) and the strengthening of continuous education and human resource development. In this webinar, we will introduce a comprehensive system that not only streamlines operations but also consistently supports education and human resource development by integrating Agatha's SOP management cloud solution "Agatha SOP" with "Ave-TMS," a training management system provided by BIO-TREND BIOPRODUCTS, with whom Agatha has recently signed a distribution agreement. [Program] Part 1: 14:00 - 14:20 "Introduction to Agatha Solutions" Agatha Inc. Sales & Marketing Department, Quality Group Part 2: 14:20 - 15:00 "Ave-TMS Demo Presentation" BIO-TREND BIOPRODUCTS Project Manager, Choi Woo-Chun *For Q&A, please fill out the survey displayed after the webinar, and we will respond later.

[Speaker] Toshio Kawamoto, Managing Director / Head of Cross Creation Group, NTT Data Management Research Institute, Business Transformation Unit, and Co-representative of Social Innovation Alliance Japan Denmark Takaaki Sukegawa, Senior Manager [Lecture Items] 1. Competitiveness and Governance in the Post-Generative AI Era - Toshio Kawamoto [13:00 - 14:00] 1. Introduction to NTT Data Management Research Institute 2. Major countries' perspectives on AI utilization 3. Considerations for companies when building AI governance 4. Examples of AI governance construction in Japan 5. Introduction of our company's achievements in related projects 6. Q&A / Business card exchange 2. On-Site AI Risk Management in Europe ~Introduction to Trends in AI Utilization in Europe and Advanced Centralized AI Risk Management Solutions~ - Takaaki Sukegawa [14:10 - 15:10] 1. Overview of centralized AI risk management 2. Detailed approach 3. Introduction of case studies applying the approach 4. Q&A / Business card exchange